Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

被引:82
|
作者
Adi, Handoko [1 ]
Young, Paul M. [1 ]
Chan, Hak-Kim [1 ]
Agus, Helen [2 ]
Traini, Daniela [1 ]
机构
[1] Univ Sydney, Adv Drug Delivery Grp, Fac Pharm A15, Sydney, NSW 2006, Australia
[2] Univ Sydney, Fac Sci G08, Sydney, NSW 2006, Australia
关键词
Mannitol; Ciprofloxacin; Dry powder inhaler (DPI); Cystic fibrosis; Antibiotics; Mucolytics; RECOMBINANT HUMAN DNASE; HIGH-DOSE IBUPROFEN; PSEUDOMONAS-AERUGINOSA; N-ACETYLCYSTEINE; LUNG-FUNCTION; MUCUS CLEARANCE; INHALATION; ANTIBIOTICS; SAFETY; INFECTION;
D O I
10.1016/j.ejps.2010.03.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to assess the potential of delivering a combination therapy, containing mannitol (a sugar alcohol with osmotic characteristics), and ciprofloxacin hydrochloride (an antibacterial fluoroquinolone), as a dry powder inhaler (DPI) formulation for inhalation. Single and combination powders were produced by spray drying ciprofloxacin and mannitol, from aqueous solution, at different ratios and under controlled conditions, as to obtain similar particle size distributions. Each formulation was characterised using laser diffraction, scanning electron microscopy, differential scanning calorimetry, dynamic vapour sorption, X-ray powder diffraction, and colloidal force microscopy. The in vitro aerosol performance of each formulation was studied using an Aerolizer (R) DPI device and a multi-stage liquid impinger (analysed using high performance liquid chromatography). In addition, a disk diffusion test was performed to assess the in vitro antimicrobial activity of each formulation and starting materials. All formulations had similar particle size distributions, however, the morphology, thermal properties and moisture sorption was dependent on the relative percentages of each component. In general, the combination formulation containing 50% (w/w) mannitol appeared to have the best aerosol performance, good stability and lowest particle cohesion (as measured by colloid probe microscopy). Furthermore, of the formulations tested, mannitol did not appear to alter the effectiveness of the ciprofloxacin antimicrobial activity to Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pyogenes. The combination of co-spray-dried mannitol and ciprofloxacin from a DPI is an attractive approach to promote mucous clearance in the respiratory tract while simultaneously treating local chronic infection, such as chronic obstructive pulmonary disease and cystic fibrosis. Crown Copyright (C) 2010 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:239 / 247
页数:9
相关论文
共 50 条
  • [21] Inappropriate Peak Inspiratory Flow Rate with Dry Powder Inhaler in Chronic Obstructive Pulmonary Disease
    Chen, Shih-Yu
    Huang, Chun-Kai
    Peng, Hui-Chuan
    Yu, Chong-Jen
    Chien, Jung-Yien
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [22] Lung Deposition Of Ciprofloxacin Dry Powder For Inhalation In Healthy Subjects And Patients Suffering From Chronic Obstructive Pulmonary Disease Or Non-Cystic Fibrosis Bronchiectasis
    Stass, H.
    Nagelschmitz, J.
    Kappeler, D.
    Weimann, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [23] Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
    S.Chennakesavulu
    A.Mishra
    A.Sudheer
    C.Sowmya
    C.Suryaprakash Reddy
    E.Bhargav
    AsianJournalofPharmaceuticalSciences, 2018, 13 (01) : 91 - 100
  • [24] Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
    Chennakesavulu, S.
    Mishra, A.
    Sudheer, A.
    Sowmya, C.
    Reddy, C. Suryaprakash
    Bhargav, E.
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 13 (01) : 91 - 100
  • [25] Development and Characterization of Spray-Dried Combined Levofloxacin-Ambroxol Dry Powder Inhaler Formulation
    Suraweera, Ruwani K.
    Spann, Kirsten M.
    Izake, Emad L.
    Wells, Timothy J.
    Wang, Xiaodong
    Islam, Nazrul
    PHARMACEUTICS, 2024, 16 (12)
  • [26] Design of Spray-dried Porous Particles for Sugar-based Dry Powder Inhaler Formulation
    Kadota, Kazunori
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2018, 138 (09): : 1163 - 1167
  • [28] Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease
    Mahler, Donald A.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (07) : 1103 - 1107
  • [29] Qualitative assessment of a two-strip dry powder inhaler for chronic obstructive pulmonary disease and asthma
    Woepse, M.
    Dale, P.
    Garrill, K.
    Svedsater, H.
    Walker, R.
    ALLERGY, 2013, 68 : 675 - 675
  • [30] Utility of peak inspiratory flow measurement for dry powder inhaler use in chronic obstructive pulmonary disease
    Loh, Chee Hong
    Ohar, Jill A.
    CURRENT OPINION IN PULMONARY MEDICINE, 2024, 30 (02) : 174 - 178